中华超声影像学杂志
中華超聲影像學雜誌
중화초성영상학잡지
CHINESE JOURNAL OF ULTRASONOGRAPHY
2014年
12期
1065-1069
,共5页
董彦%常才%强金伟%周世崇%乐坚
董彥%常纔%彊金偉%週世崇%樂堅
동언%상재%강금위%주세숭%악견
超声检查%乳腺肿瘤%化学疗法,辅助%超声光散射
超聲檢查%乳腺腫瘤%化學療法,輔助%超聲光散射
초성검사%유선종류%화학요법,보조%초성광산사
Ultrasonography%Breast neoplasms%Chemotherapy,adjuvant%US-diffuse optical tomography
目的 探讨超声光散射成像技术(US-DOT)用于评估乳腺癌新辅助化疗(NCT)效果的可行性.方法 乳腺癌NCT病例50例,按照化疗后的临床疗效评价标准分为完全缓解(CR)组、部分缓解(PR)组、稳定(SD)组、进展(PD)组.对于50例乳腺原发病灶进行化疗前后的US-DOT检查,检测肿瘤血红蛋白总量(HbT)值.用方差分析比较各组治疗前后HbT的差异;用Pearson相关分析HbT相对变化量与肿瘤直径变化的关系;用混合效应模型评估HbT值和肿瘤直径的关系.结果 NCT结束后,50例患者中CR组8例,PR组30例,SD组12例,PD组0例.化疗前后肿瘤直径和HbT在CR组与PR组差异均有统计学意义(P ＜0.001),而在SD组两者差异均无统计学意义(P＞0.05).化疗后CR组HbT相对变化比的平均值为-0.525±0.222,PR组为-0.328±0.180,SD组为-0.173±0.167,组间比较差异具有统计学意义(P＜0.05).Pearson相关分析显示NCT结束后肿瘤HbT值下降,其直径亦下降,肿瘤HbT相对变化比与直径的变化具有相关性(r=0.6).混合效应模型也表明肿瘤HbT与直径的变化相关且趋势一致.结论 US-DOT参数HbT与肿瘤直径密切相关,可用于评估乳腺癌新辅助化疗的疗效.
目的 探討超聲光散射成像技術(US-DOT)用于評估乳腺癌新輔助化療(NCT)效果的可行性.方法 乳腺癌NCT病例50例,按照化療後的臨床療效評價標準分為完全緩解(CR)組、部分緩解(PR)組、穩定(SD)組、進展(PD)組.對于50例乳腺原髮病竈進行化療前後的US-DOT檢查,檢測腫瘤血紅蛋白總量(HbT)值.用方差分析比較各組治療前後HbT的差異;用Pearson相關分析HbT相對變化量與腫瘤直徑變化的關繫;用混閤效應模型評估HbT值和腫瘤直徑的關繫.結果 NCT結束後,50例患者中CR組8例,PR組30例,SD組12例,PD組0例.化療前後腫瘤直徑和HbT在CR組與PR組差異均有統計學意義(P ＜0.001),而在SD組兩者差異均無統計學意義(P＞0.05).化療後CR組HbT相對變化比的平均值為-0.525±0.222,PR組為-0.328±0.180,SD組為-0.173±0.167,組間比較差異具有統計學意義(P＜0.05).Pearson相關分析顯示NCT結束後腫瘤HbT值下降,其直徑亦下降,腫瘤HbT相對變化比與直徑的變化具有相關性(r=0.6).混閤效應模型也錶明腫瘤HbT與直徑的變化相關且趨勢一緻.結論 US-DOT參數HbT與腫瘤直徑密切相關,可用于評估乳腺癌新輔助化療的療效.
목적 탐토초성광산사성상기술(US-DOT)용우평고유선암신보조화료(NCT)효과적가행성.방법 유선암NCT병례50례,안조화료후적림상료효평개표준분위완전완해(CR)조、부분완해(PR)조、은정(SD)조、진전(PD)조.대우50례유선원발병조진행화료전후적US-DOT검사,검측종류혈홍단백총량(HbT)치.용방차분석비교각조치료전후HbT적차이;용Pearson상관분석HbT상대변화량여종류직경변화적관계;용혼합효응모형평고HbT치화종류직경적관계.결과 NCT결속후,50례환자중CR조8례,PR조30례,SD조12례,PD조0례.화료전후종류직경화HbT재CR조여PR조차이균유통계학의의(P ＜0.001),이재SD조량자차이균무통계학의의(P＞0.05).화료후CR조HbT상대변화비적평균치위-0.525±0.222,PR조위-0.328±0.180,SD조위-0.173±0.167,조간비교차이구유통계학의의(P＜0.05).Pearson상관분석현시NCT결속후종류HbT치하강,기직경역하강,종류HbT상대변화비여직경적변화구유상관성(r=0.6).혼합효응모형야표명종류HbT여직경적변화상관차추세일치.결론 US-DOT삼수HbT여종류직경밀절상관,가용우평고유선암신보조화료적료효.
Objective To investigate the value of ultrasound-diffuse optical tomography(US-DOT) in evaluation of the response to neoadjuvant chemotherapy (NCT) in patients with breast cancer.Methods Fifty women with breast cancer confirmed by biopsy-pathology scheduled to undergo NCT were enrolled.US-DOT was performed and the total hemoglobin concentration(HbT) prior to and at the end of NCT.According to the response to treatment in solid tumors,patients were divided into complete response(CR) group,partial response (PR) group,stable disease (SD) group and progressive disease (PD) group.The analysis of variance compared the differences of HbT before and after NCT in each group; Pearson correlation analyzed the relationship between the relative HbT variation and the tumor size changes;Mixedeffects model analyzed the relationship between HbT and tumor size.Results After NCT,CR group had 8 cases,PR group 30 cases,SD group 12 cases and no PD cases.Before and after NCT,the mean relative variations of HbT before and after NCT were-0.525 ± 0.222,-0.328 ± 0.180 and-0.173 ± 0.167 in CR,PR and SD groups,respectively.The differences of HbT before and after NCT were statistically significant in each group (P ＜0.05).There was significant difference among tumor diameter and HbT in CR group and PR group (P ＜0.001);while in the SD group,there was no difference among tumor diameter and HbT (P ＞ 0.05).The change of HbT after NCT showed positive correlation with the change in tumor size (r =0.6).Mixed-effects model also showed that HbT change was associated with tumor size.Conclusions USDOT marker HbT is closely related to tumor size of breast cancer before and after NCT and may be applied to evaluate the response of breast cancer to NCT.
